tbuckley/cabot-search huggingface dataset:
BMET-36. OPTIMAL RADIOSURGERY DOSE FOR TREATMENT OF MELANOMA AND RENAL CELL CARCINOMA METASTASES
Authors: Brian Hirshman, Bayard Wilson, Mir Amaan Ali, James Proudfoot, Takao Koiso, Osamu Nagano, Toru Serizawa, Masaaki Yamamoto, Bob Carter, Clark Chen
Journal: Neuro-Oncology (2016)

While brain metastases (BM) that emerged from melanoma and renal cell carcinoma (RCC) are generally considered to be radiation resistant, the stereotactic radiosurgery (SRS) dose required for optimal treatment remain poorly defined. We analyzed the association between overall survival and radiosurgery dose in 334 melanoma and 360 RCC patients with BM treated with SRS at the University of California San Diego (USA), the Melanoma Institute of Australia (Australia), Katsuta Hospital Mito GammaHouse (Japan), and Tsukiji Neurological Clinic (Japan). Survival analysis was performed using established statistical measures, including continuous Net Reclassification Improvement (NRI>0) and Integrated Discrimination Index (IDI). Our analysis validated the prognostic value of the disease-specific Graded Prognostic Assessment (ds-GPA) scale for melanoma and RCC (both scales consisted of KPS and number of brain metastasis). We further demonstrated that the incorporation of the cumulative intracranial tumor volume (CITV) enhanced the prognostic value of ds-GPA for melanoma and RCC (p<0.05 for NRI>0 and IDI). In a statistical model that controlled for KPS, number of metastasis, and CITV, radiosurgery dose exceeding 18 Gy was associated with improved survival in RCC patients. For melanoma, dose exceeding 22 Gy was associated with improved overall survival. We demonstrate that the prognostic value of ds-GPA can be enhanced by incorporation of CITV. In a CITV-modified ds-GPA model, dose exceeding 18 Gy was associated with improved survival in RCC patients. For melanoma patients, survival association was observed with dose ­exceeding 22 Gy.
Evaluation of polyesteramide (PEA) and polyester (PLGA) microspheres as intravitreal drug delivery systems in albino rats
Authors: Tobias Peters, Seong-Woo Kim, Vinicius Castro, Krunoslav Stingl, Torsten Strasser, Sylvia Bolz, Ulrich Schraermeyer, George Mihov, MengMeng Zong, Vanessa Andres-Guerrero, Rocio Herrero Vanrell, Aylvin A. Dias, Neil R. Cameron, Eberhart Zrenner
Journal: Biomaterials (2017)
Distinct roles for TET family proteins in regulating human erythropoiesis
Authors: Hongxia Yan, Yaomei Wang, Xiaoli Qu, Jie Li, John Hale, Yumin Huang, Chao An, Julien Papoin, Xinhua Guo, Lixiang Chen, Qiaozhen Kang, Wei Li, Vincent P. Schulz, Patrick G. Gallagher, Christopher D. Hillyer, Narla Mohandas, Xiuli An
Journal: Blood (2017)
Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece.
Authors: Michalis Michail, Efstathios Kastritis, Sossana Delimpassi, Marie Christine Kyrtsonis, Evridiki Michali, Nicolaos Anagnostopoulos, Konstantinos Zervas, Eirini Katodritou, Panagiotis Panagiotidis, Natalia Tzenou, Gerassimos Pangalis, Meletios Athanasios Dimopoulos
Journal: Blood (2007)
Factors influencing treatment of inflammatory breast cancer in the United States.
Authors: Heather Y. Lin, Gildy Babiera, Isabelle Bedrosian, Simona Flora Shaitelman, Henry Mark Kuerer, Wendy A. Woodward, Naoto T. Ueno, Yu Shen
Journal: Journal of Clinical Oncology (2015)

118 Background: Guidelines for treating inflammatory breast cancer (IBC) using trimodality (chemotherapy, surgery and radiation) therapy (TT) remain largely unchanged since 2000. However, many such patients did not receive TT. It is unknown how patient-level (PL) and facility-level (FL) factors contribute to TT utilization. Methods: Using the National Cancer Data Base (NCDB), patients who underwent surgical treatment of locoregional IBC from 2003-2011 were identified. We correlated patient, tumor, and treatment data with TT. An observed to expected (O/E) ratio of number of patients treated with TT was calculated for each hospital by adjusting for PL factors. Hierarchical mixed effects models were used to assess the proportion of variation in the use of TT attributable to PL and FL factors, respectively. Results: Among 5,537 patients who met the study criteria, the use of TT fluctuated annually (67.3%-75.7%) and was less likely for patients who were over 70, had a lower income or had an N0 tumor (all p &lt; 0.05). By insurance type, TT use was lowest among Medicare patients. Of the 542 hospitals examined, 55 (10.1%) and 24 (4.4%) were identified as significantly low and high outliers for the use of TT (p &lt; 0.05), respectively. While comprehensive cancer centers represented the majority of high outliers, the TT use by facility type overall was not significantly different demonstrating variability within comprehensive cancer center practice. The percentage of the total variance in the use of TT attributable to facility (11%) was almost triple the variance attributable to the measured PL factors (3.4%). Conclusions: The use of standard of care TT varied widely across facilities with some high volume centers clearly underutilizing TT. To improve clinical outcomes for this rare and aggressive malignancy, it is critical to identify facility level factors impacting the use of TT to ensure the guideline adherence of IBC treatment.
Gender as a Prognostic Factor in CLL. Biological Pointers to the Improved Outcome of Women.
Authors: Daniel Catovsky, Estella Matutes, Alison Morilla, Anna Burford, Vasantha Brito-Babapulle, Ilaria Del-Giudice, Jennifer Orchard, David G. Oscier, Jim Halsey, Sue Richards
Journal: Blood (2004)
Phase I trial of daily imatinib mesylate and weekly paclitaxel in patients with advanced refractory solid tumors
Authors: A. Bahrani, J. Hwang, S. Malik, J. L. Marshall
Journal: Journal of Clinical Oncology (2004)

3087 Background: Inhibition of PDGF receptors by a selective PDGF receptor kinase inhibitor (such as Gleevec) decreases the interstitial pressure of tumor and increases capillary-to-interstitial transport of low molecular mass compounds such as EDTA. Combination of Gleevec(G) and paclitaxel(P) has resulted in enhancement of P activity against s.c.KAT-4 tumors in SCID mice. Myelosupression of G has prevented successful combination therapy with cytotoxic agents such as gemcitabine and doxorubicine. Methods: This phase I clinical trial studies the pharmacokinetics (PK) and toxicities of the combination of G and P in patients (pts) with advanced solid tumors. At dose level (DL) 1, pts received G daily in combination with P on days 1, 8, and 15, given every 28 days. Results: 6 pts were enrolled at DL 1 (G 400mg, P 60 mg/m2). 5 pts developed grade III neutropenia. The neutropenia caused significant delay in treatment and dose escalation was not possible. 5 pts were enrolled to DL -1 (G 300 mg, P 60 mg/m2), one pt developed G III neutropenia. No DLT's have been observed. Other toxicities observed include: gr1 fatigue (all pts), gr1 nausea (9 pts), gr 2 alopecia (2 pts), gr 2 rash ( 1 pt), gr 2 diarrhea ( 2 pts), gr 1 neuropathy (2 pts).Two patients had a PR (both on cycle 6, one has NSCL cancer and the other esophageal cancer ) and one has had stable disease (on cycle 4, colon carcinoma).Preliminary PK analysis has not shown any clear effect of G on P. In order to dose escalate but maintain PDGF inhibition, we amended the protocol to G 400 mg on D1–4 and P on D 3,10 and 17. Three pts have been evaluated on this DL (DL 1A, G 400 mg D1–4 and P 60 mg/m2 D3, D10, D17). None has developed grade II or higher neutropenia and accrual to the next dose level is now ongoing. Conclusions: Neutropenia appears to be the main obstacle in combining daily G with chemotherapy agents such as P, even at low doses. Administration of G on intermittent schedule with chemotherapy may avoid significant neutropenia, allowing combination of G with desired doses of cytotoxic agents. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis; Roche Novartis; Roche Novartis
Early palliative care involvement for children with cancer.
Authors: Laila Mahmood, Ann Dozier, James Dolan, Denise Casey, David Nathan Korones
Journal: Journal of Clinical Oncology (2014)

26 Background: Although the overall survival of children with cancer exceeds 80%, these children experience significant physical, emotional, social and spiritual suffering. That suffering is even more profound for the 20% of children who succumb to their disease. We therefore conducted a prospective study to assess the feasibility and impact of early palliative care involvement for children with high risk malignancies. Objective: To determine if early palliative care involvement for high risk pediatric oncology patients is feasible, acceptable to patients, families and oncology teams, and helps with symptom management and communication. Methods: This was a prospective survey-based study. Children with cancer treated at University of Rochester were eligible to participate if they had a high risk malignancy, defined as (1) having a newly-diagnosed malignancy with an estimated overall survival of &lt; 50%, (2) requiring hematopoietic stem cell transplantation (HSCT), and/or (3) any relapsed, recurrent or progressive cancer. Parents of these children or children &gt;18YO were surveyed upon study entry, and 3 and 6 months later to assess the impact of early and ongoing pediatric palliative care involvement. Results: 20/25 eligible patients received a palliative care consultation at diagnosis; 16 families participated in the study. Six children had a newly diagnosed high risk malignancy, nine had recurrent disease and one child had a HSCT. Median age of the children was 5 years (0.1-20 year).The most frequent symptoms at the time of study entry were pain (75%), nausea/vomiting (69%), constipation (44%), and fatigue (44%). 75%, 73%, 43% and 43% reported successful treatment of pain, nausea/vomiting, constipation, and fatigue respectively. The proportion of children with each symptom decreased at 3 months except for fatigue. There was high satisfaction with the oncology and pediatric palliative care teams at baseline and 3 and 6 months. No families or oncologists declined an early palliative care consultation. Conclusions: Our results suggest that an early palliative care consultation is feasible for high risk children with cancer and that the palliative care team can work successfully with the primary oncology team to foster symptom control and communication.
Enabling successful T-cell therapy of solid tumors with oncolytic adenoviruses armed with TNF&amp;agr; and IL-2
Authors: A. Hemminki, R. Havunen, M. Siurala, S. Tähtinen, D. Saha, M. Vähä-Koskela, M. Behr, D. Nettelbeck, A. Ehrhardt, S. Parviainen
Journal: Annals of Oncology (2016)
Filanesib Primarily Initiates the Apoptotic Program By Activating Bax through a Calpain-Dependent Mechanism
Authors: Susana Hernández-García, Lorena González-Méndez, Irena Misiewicz-Krzeminska, Esperanza Macarena Algarín, Ana Alicia López-Iglesias, Laura San-Segundo, Montserrat Martín-Sánchez, Teresa Paíno, Norma C Gutierrez, Mercedes Garayoa, Brian Tunquist, Maria-Victoria Mateos, Enrique M Ocio
Journal: Blood (2015)
Capturing and addressing emotional well-being: Utilization of ASCO’s Quality Oncology Practice Initiative (QOPI) for performance improvement.
Authors: Patricia D. Hegedus, James D. Bearden, Bruce Grant
Journal: Journal of Clinical Oncology (2012)

207 Background: Palmetto Hematology Oncology (PHO) is the medical oncology practice of Spartanburg Regional Healthcare System (SRHS) and has participated in QOPI since 2009 and earned QOPI certification in September 2011. Emotional well-being assessments and documentation of interventions were selected for a performance improvement project based on QOPI measures from Fall 2009. Methods: Several articles were identified supporting the use of the NCCN Distress Thermometer following a comprehensive literature search and approval was obtained for use. The NCCN Distress Thermometer was administered to all new patients through inclusion in “new patient” paperwork packets. Two physician offices within the practice were piloted with the physicians reviewing the patient reported assessments and documenting any required interventions. All completed NCCN Distress Thermometer forms were also reviewed by the medical social work team, and for scores &gt; 3, interventions by phone or face-to-face were completed by them and documented in the patients’ electronic medical records. Results: Due to the success of the pilot efforts the assessment/intervention process for emotional well-being was expanded throughout the PHO practice, the Gibbs Infusion Center, and Radiation Oncology. The QOPI emotional well-being indicator revealed an increase from the Fall 2009 to Spring 2012 of 36.25% to 96.25%. Conversely, our compliance with intervention by the second office visit decreased from 94.44% to 69.44%, respectively. Conclusions: Although PHO’s scores for the emotional well-being assessment have dramatically improved with implementation of the process improvement initiative, opportunity remains for improving emotional well-being intervention documentation. This initiative highlighted the lack of psychiatric/psychological services available to PHO patients. References: NCCN Clinical Practice Guidelines in Oncology: Distress Management, Version 3.2012; Available at: http://www.nccn.org/professionals/physician_gls/pdf/distress.pdf . QOPI The Quality Oncology Practice Initiative; Available at: http://qopi.asco.org/program .
Abstract P6-09-54: Long-term recurrence risk and risk-based follow-up after breast cancer treatment
Authors: S Siesling, A Witteveen, L de Munck, K Groothuis-Oudshoorn, G Sonke, J Klaase, L Boersma, P Poortmans, M IJzerman
Journal: Cancer Research (2017)

Abstract This abstract was not presented at the symposium.
Clinical Features for Heterozygosity of the Common β Globin Gene Frameshift 41/42 Mutation: Identification and Properties of Hb Salouël (β[Phe41Leu;Val59X])
Authors: Jacques Rochette, Estelle Cadet, Francis Boitte, Najeh El Esper, Claire Presne, Patricia Bignet, Christine Cézard
Journal: Blood (2008)
Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.
Authors: Philippe Solal-Celigny, Gilles Andre Salles, Nicole Brousse, Patricia Franchi-Rezgui, Pierre Soubeyran, Vincent Delwail, Eric Deconinck, Corinne Haioun, Charles Foussard, Catherine Sebban, Herve Tilly, Noel-Jean Milpied, Francois Boue, Jean-Michel Karsenti, Pierre Lederlin, Albert Najman, Catherine Thieblemont, Franck Morschhauser, Nathalie Berriot-Varoqueaux, Loic Bergougnoux, Philippe Colombat
Journal: Blood (2004)
Breast cancer Ki67, tumor size and axillary nodes relationship: it's complicated
Authors: G. Bregni, E. Meneghini, G. Galli, S. Cavalieri, F. Di Salvo, H. Amash, B. Paolini, F.G.M. De Braud, M.C. De Santis, M. Sant, S. Di Cosimo
Journal: Annals of Oncology (2016)
Switch from Intravenous C1-Inhibitor C1-INH(IV) to Subcutaneous C1-Inhibitor [C1 INH(SC)] for Routine Prevention of Hereditary Angioedema (HAE) Attacks: Subgroup Findings from the Compact Trial
Authors: Timothy J. Craig, James W. Baker, William R. Lumry, Henriette Farkas, Henrike Feuersenger, Iris Jacobs
Journal: Journal of Allergy and Clinical Immunology (2017)
Cancers of the Nasopharynx and Oropharynx and Formaldehyde Exposure: Reply
Authors: James J. Collins, D. Utidijian
Journal: JNCI Journal of the National Cancer Institute (1987)

Journal Article Cancers of the Nasopharynx and Oropharynx and Formaldehyde Exposure: Reply Get access James J. Collins, James J. Collins Search for other works by this author on: Oxford Academic PubMed Google Scholar D. Utidijian D. Utidijian Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 78, Issue 1, January 1987, Pages 192–193, https://doi.org/10.1093/jnci/78.1.192 Published: 01 January 1987
Trisomy 8 in the Light of Recent Cytogenetic Classification Advances. A Study From the French Acute Myeloid Leukemia Intergroup.
Authors: Nicolas Boissel, Christine Terré, Pascale Cornillet-Lefebvre, Odile Maarek, Eric Lippert, Isabelle Tigaud, Nicole Dastugue, Claude Preudhomme, Norbert Ifrah, Hervé Dombret, Isabelle Luquet
Journal: Blood (2009)
Dendritic Cells Cross-Present Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Functional T Cell Immunity
Authors: Alastair Hotblack, Sara Seshadri, Lei Zhang, Sahar Hamrang-Yousefi, Ronjon Chakraverty, David Escors, Clare L. Bennett
Journal: Molecular Therapy (2017)

Recombinant lentiviral vectors (LVs) are highly effective vaccination vehicles that elicit protective T cell immunity in disease models. Dendritic cells (DCs) acquire antigen at sites of vaccination and migrate to draining lymph nodes, where they prime vaccine-specific T cells. The potency with which LVs activate CD8+ T cell immunity has been attributed to the transduction of DCs at the immunization site and durable presentation of LV-encoded antigens. However, it is not known how LV-encoded antigens continue to be presented to T cells once directly transduced DCs have turned over. Here, we report that LV-encoded antigen is efficiently cross-presented by DCs in vitro. We have further exploited the temporal depletion of DCs in the murine CD11c.DTR (diphtheria toxin receptor) model to demonstrate that repopulating DCs that were absent at the time of immunization cross-present LV-encoded antigen to T cells in vivo. Indirect presentation of antigen from transduced cells by DCs is sufficient to prime functional effector T cells that control tumor growth. These data suggest that DCs cross-present immunogenic antigen from LV-transduced cells, thereby facilitating prolonged activation of T cells in the absence of circulating LV particles. These are findings that may impact on the future design of LV vaccination strategies. Recombinant lentiviral vectors (LVs) are highly effective vaccination vehicles that elicit protective T cell immunity in disease models. Dendritic cells (DCs) acquire antigen at sites of vaccination and migrate to draining lymph nodes, where they prime vaccine-specific T cells. The potency with which LVs activate CD8+ T cell immunity has been attributed to the transduction of DCs at the immunization site and durable presentation of LV-encoded antigens. However, it is not known how LV-encoded antigens continue to be presented to T cells once directly transduced DCs have turned over. Here, we report that LV-encoded antigen is efficiently cross-presented by DCs in vitro. We have further exploited the temporal depletion of DCs in the murine CD11c.DTR (diphtheria toxin receptor) model to demonstrate that repopulating DCs that were absent at the time of immunization cross-present LV-encoded antigen to T cells in vivo. Indirect presentation of antigen from transduced cells by DCs is sufficient to prime functional effector T cells that control tumor growth. These data suggest that DCs cross-present immunogenic antigen from LV-transduced cells, thereby facilitating prolonged activation of T cells in the absence of circulating LV particles. These are findings that may impact on the future design of LV vaccination strategies.
A retrospective Review of the Outcomes of 2 years of Oral Food Challenges in Children Under Two Years old
Authors: Ryan Barson, Irene Mikhail, Rebecca Scherzer
Journal: Journal of Allergy and Clinical Immunology (2017)

The gold standard in the diagnosis of food allergy is an oral food challenge (OFC). Recent studies have advocated for early introduction of allergenic foods, potentially leading to an increase in OFCs in young children. A chart review was conducted on all patients younger than 2 years old who underwent an OFC from July 1, 2014 - June 30, 2016. There were 92 OFCs performed in children under two years of age over the 2-year period. We excluded 10 challenges performed for the evaluation of non-IgE mediated reactions. There were 44(54%) male patients and 22(30%) were under the age of 12 months at the time of challenge. The majority of OFC were directed at peanut 27(33%). Other foods challenged include: baked egg 21(26%), dairy 7(9%), wheat 5(6%), baked milk 5(6%) and egg 5(6%). Fifty-seven (70 %) of the patients had additional known food allergens and 55(67%) were noted to have atopic dermatitis. There were 19(23 %) positive, 54(66 %) negative, and 9( 11%) incomplete challenges. In the group of failed challenges, 6(32%) required treatment with epinephrine. The majority of challenges were aimed at introducing peanut or baked egg. Not surprisingly, a significant number of patients were noted to have other food allergies or atopic dermatitis, which can be risk factors for developing peanut allergy. We found that 11% of the challenges could not be completed due to patient refusal, highlighting a potential obstacle in performing challenges in young children. The majority of positive challenges did not require treatment with epinephrine.
Tie2Cre B-Raf flox/flox Mice Reveal a Role for B-Raf in Tpo-Mediated Thrombopoiesis and Survival of Mature Megakaryocytes in Adult Hematopoiesis.
Authors: Tamihiro Kamata, Jing Kang, Alcino Silva, Rong Wang, Andrew D. Leavitt
Journal: Blood (2005)
IL-33 and IL-13 Receptors Are Upregulated in Precision Cut Lung Slices from Donors with Asthma during RV39 Infection
Authors: Jamie L. Waldron, Dorothy J. Currey, Suzanne E. House, James D. Sikes, Stacie M. Jones, Richard Kurten, Joshua Kennedy
Journal: Journal of Allergy and Clinical Immunology (2017)
Intrinsic subtype and response to neoadjuvant chemotherapy with carboplatin and docetaxel (TCb) in triple-negative breast cancer (TNBC)
Authors: I. Echavarria Diaz-Guardamino, S. Lopez-Tarruella, J.A. García-Sáenz, H. Gomez Moreno, F. Moreno, Y. Jerez, H. Fuentes, I. Marquez-Rodas, M. Cebollero, M. Del Monte-Millan, A. Picornell, T. Massarrah, A. Barnadas, A. Prat, A. Ballesteros García, R. Colomer Bosch, B. Pelaez, M. González-Rivera, C.M. Perou, M. Martin
Journal: Annals of Oncology (2016)
HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.
Authors: Steven M. Devine, Ravi Vij, Laura Todt, Kiley McLaughlin, Nicholas Fisher, Natalie Morris, Daniel C. Link, Gary Calandra, Gary Bridger, John F. DiPersio
Journal: Blood (2006)